Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing vidutolimod, an intratumoral TLR9 agonist immunotherapy, intended for use in combination with checkpoint inhibitors across multiple solid tumor indications. The company is pre-revenue and is currently delisted from public markets.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Checkmate Pharmaceuticals does
Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2015 and based in Cambridge, Massachusetts, that develops intratumoral cancer immunotherapies designed to be administered directly into tumors and used in combination with immune checkpoint inhibitors such as anti-PD-1 antibodies. The company's lead clinical candidate, vidutolimod (CMP-CPS-001), is a Toll-like receptor 9 (TLR9) agonist intended to convert "cold" tumor microenvironments into immune-active ones, thereby enhancing the activity of systemic checkpoint blockade across multiple solid tumor indications. The pipeline strategy is explicitly combination-focused: vidutolimod is positioned not as a standalone agent but as a complementary modality to established PD-1/PD-L1 inhibitors, targeting indications such as melanoma, non-small cell lung cancer, and other solid tumors in investigator- and company-sponsored clinical trials.
The company is pre-revenue, with no approved products and no commercial sales infrastructure; its only monetization pathway is via future out-licensing, partnership milestones, or royalty arrangements with large pharma partners following clinical proof-of-concept. Between 2015 and 2020 Checkmate raised approximately $170 million across multiple private rounds and an initial public offering on NASDAQ (ticker CMPI), backed by specialist life-sciences investors including F-Prime, venBio Partners, Sofinnova Investments, Decheng Capital, Longitude Capital, and Novo Holdings. Leadership is concentrated in a small executive team of 11-50 employees, anchored by founder and Chief Scientific Officer Art Krieg, an established immunology and oligonucleotide therapeutics researcher. The company is currently delisted from NASDAQ, with no post-2020 operational, clinical, or financial disclosures available in the input data.
Checkmate Pharmaceuticals firmographics
Firmographics- Name
- Checkmate Pharmaceuticals
- Legal name
- Checkmate Pharmaceuticals
- Website
- https://checkmatepharma.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing vidutolimod, an intratumoral TLR9 agonist immunotherapy, intended for use in combination with checkpoint inhibitors across multiple solid tumor indications. The company is pre-revenue and is currently delisted from public markets.
- Ownership category
- akta.pro rank
Checkmate Pharmaceuticals industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where Checkmate Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Checkmate Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Checkmate Pharmaceuticals product offering
Product offeringCore offering
Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing intratumoral cancer immunotherapies, with research focus on combination strategies that pair immune checkpoint inhibitors with innate immunity-targeting agents to treat solid tumors.
Differentiator
Problem solved
Functional benefit
Companies that use Checkmate Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Checkmate Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Checkmate Pharmaceuticals partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Checkmate Pharmaceuticals competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Checkmate Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Checkmate Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Checkmate Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Checkmate Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Checkmate Pharmaceuticals
What does Checkmate Pharmaceuticals do?
Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing intratumoral cancer immunotherapies, with research focus on combination strategies that pair immune checkpoint inhibitors with innate immunity-targeting agents to treat solid tumors.
Is Checkmate Pharmaceuticals a public or private company?
Checkmate Pharmaceuticals is a private company. It is classified as unknown and is currently operating.
When was Checkmate Pharmaceuticals founded?
Checkmate Pharmaceuticals was founded in 2015. It employs 11 to 50 people.
Where is Checkmate Pharmaceuticals based?
Checkmate Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.
Does Checkmate Pharmaceuticals have an API?
No public API is recorded for Checkmate Pharmaceuticals.
What industry is Checkmate Pharmaceuticals in?
Checkmate Pharmaceuticals's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2834.